Tecan Group (TECN) Stock Overview
Provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
TECN Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Tecan Group AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 133.00 |
| 52 Week High | CHF 248.00 |
| 52 Week Low | CHF 131.50 |
| Beta | 1.28 |
| 1 Month Change | -11.33% |
| 3 Month Change | -23.65% |
| 1 Year Change | -36.73% |
| 3 Year Change | -68.33% |
| 5 Year Change | -65.77% |
| Change since IPO | 183.58% |
Recent News & Updates
Tecan Group AG's (VTX:TECN) Intrinsic Value Is Potentially 90% Above Its Share Price
Nov 06
Should You Investigate Tecan Group AG (VTX:TECN) At CHF150?
Oct 22Recent updates
Tecan Group AG's (VTX:TECN) Intrinsic Value Is Potentially 90% Above Its Share Price
Nov 06Should You Investigate Tecan Group AG (VTX:TECN) At CHF150?
Oct 22Tecan Group (VTX:TECN) Has A Pretty Healthy Balance Sheet
Sep 04Weak Statutory Earnings May Not Tell The Whole Story For Tecan Group (VTX:TECN)
Aug 20Tecan Group AG's (VTX:TECN) Intrinsic Value Is Potentially 81% Above Its Share Price
Aug 08Why We're Not Concerned About Tecan Group AG's (VTX:TECN) Share Price
Jul 21At CHF170, Is Tecan Group AG (VTX:TECN) Worth Looking At Closely?
May 28Is Tecan Group AG (VTX:TECN) Trading At A 26% Discount?
Apr 24Tecan Group AG (VTX:TECN) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless
Apr 08Here's Why Shareholders Should Examine Tecan Group AG's (VTX:TECN) CEO Compensation Package More Closely
Apr 04Is Tecan Group (VTX:TECN) Using Too Much Debt?
Apr 01
Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production
Expansion into South Korea and FDA approval in Malaysia bolster Tecan's production and revenue growth potential in medical devices.Tecan Group AG's (VTX:TECN) Share Price Could Signal Some Risk
Jan 12A Look At The Fair Value Of Tecan Group AG (VTX:TECN)
Dec 21Tecan Group AG's (VTX:TECN) P/E Still Appears To Be Reasonable
Oct 09These 4 Measures Indicate That Tecan Group (VTX:TECN) Is Using Debt Reasonably Well
Sep 21Earnings Report: Tecan Group AG Missed Revenue Estimates By 8.8%
Aug 16Is Tecan Group (VTX:TECN) Using Too Much Debt?
Jun 14Calculating The Fair Value Of Tecan Group AG (VTX:TECN)
Apr 20Tecan Group AG's (VTX:TECN) Business Is Yet to Catch Up With Its Share Price
Apr 02Tecan Group (VTX:TECN) Could Easily Take On More Debt
Dec 05A Look At The Intrinsic Value Of Tecan Group AG (VTX:TECN)
Nov 15Tecan Group (VTX:TECN) Could Easily Take On More Debt
Sep 01Tecan Group AG's (VTX:TECN) Intrinsic Value Is Potentially 37% Above Its Share Price
Aug 11Tecan Group (VTX:TECN) Seems To Use Debt Rather Sparingly
May 26Why We Think Shareholders May Be Considering Bumping Up Tecan Group AG's (VTX:TECN) CEO Compensation
Apr 11Here's Why Tecan Group (VTX:TECN) Can Manage Its Debt Responsibly
Dec 02Is Tecan Group (VTX:TECN) Using Too Much Debt?
Sep 02Should You Be Adding Tecan Group (VTX:TECN) To Your Watchlist Today?
Jun 15Shareholder Returns
| TECN | CH Life Sciences | CH Market | |
|---|---|---|---|
| 7D | -6.1% | -4.4% | -1.5% |
| 1Y | -36.7% | -8.5% | 7.4% |
Return vs Industry: TECN underperformed the Swiss Life Sciences industry which returned -7.9% over the past year.
Return vs Market: TECN underperformed the Swiss Market which returned 7.5% over the past year.
Price Volatility
| TECN volatility | |
|---|---|
| TECN Average Weekly Movement | 4.0% |
| Life Sciences Industry Average Movement | 4.0% |
| Market Average Movement | 3.4% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: TECN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: TECN's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 3,000 | Monica Manotas | www.tecan.com |
Tecan Group AG provides laboratory instruments and solutions in biopharmaceuticals, forensics, and clinical diagnostics in Europe, North America, Asia, and internationally. It operates in two segments, Life Sciences Business and Partnering Business. The company offers liquid handling and automation, microplate readers and washers, software, consumables, NGS reagents, immunoassays and antibodies, and Tecan Labwerx, an end-to-end automation solution.
Tecan Group AG Fundamentals Summary
| TECN fundamental statistics | |
|---|---|
| Market cap | CHF 1.69b |
| Earnings (TTM) | CHF 63.13m |
| Revenue (TTM) | CHF 906.60m |
Is TECN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TECN income statement (TTM) | |
|---|---|
| Revenue | CHF 906.60m |
| Cost of Revenue | CHF 587.57m |
| Gross Profit | CHF 319.03m |
| Other Expenses | CHF 255.90m |
| Earnings | CHF 63.13m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Mar 16, 2026
| Earnings per share (EPS) | 4.97 |
| Gross Margin | 35.19% |
| Net Profit Margin | 6.96% |
| Debt/Equity Ratio | 19.5% |
How did TECN perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/20 04:06 |
| End of Day Share Price | 2025/11/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Tecan Group AG is covered by 22 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Markus Mayer | Baader Helvea Equity Research |
| Leonildo Delgado | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |